For all Dermatology Times conference updates and news, subscribe to receive our eNewsletters.

Day 1

Almirall Showcases Therapeutic Innovations at AAD 2025

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Adewole Adamson, MD, MPP: Getting Ready to Tackle Dermatology's Key Challenges Issues at AAD 2025

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Exploring the IBD-Dermatology Connection

Alexandra P. Charrow, MD, FAAD, shares insights on the link between dermatology and irritable bowel disease at the AAD Annual Meeting.

AAD Announces Newly Appointed Leadership Officers

In addition to Taylor, several other new leaders have been appointed to key roles within the AAD to help drive its mission of advancing dermatology.

Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.

Early-Career Tips for Attending AAD 2025

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Day 2

Alexandra P Charrow, MD, FAAD, Discusses Complex Medical Dermatology, HS at AAD Annual Meeting

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.

Jeff Stark, MD: Reviewing UCB's Abstracts Across HS, PsO, PsA, and More

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Tapinarof Extends Symptom-Free Periods in Patients with AD

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

Adewole Adamson, MD, MPP: Addressing Melanoma Diagnosis and Overdiagnosis

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Late Breaking: Data From Pivotal Trial Reports Dupilumab Effective for Bullous Pemphigoid

Late breaking data points to positive data for dupilumab for bullous pemphigoid.

Dermatologist Creates AI Tool to Make Documentation Easier

Michael Sherling, MD, MBA, leverages AI to simplify administrative tasks and focus on patient care.

Late-Breaking Data: Super Responders With Delgocitinib for CHE

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Day 3

Upadacitinib Shows Biomarker-Driven Efficacy in Nonsegmental Vitiligo

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Risankizumab Maintains High Skin Clearance Over 36 Months

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Advances in Treatment Resistant Port-Wine Birthmarks: Emerging Therapies and Future Directions

Expect exciting news in the treatment of port-wine birthmarks, Kristen Marie Kelly, MD, told AAD Annual Meeting attendees.

Advancing Recognition and Treatment of Allergic Contact Dermatitis

JiaDe Yu, MD, discussed important clinical issues in allergic contact dermatitis at the AAD Annual Meeting.

Early Intervention for Port-Wine Stains

At the AAD Annual Meeting, Roy G. Geronemus, MD, emphasized the importance of early interventions for port wine stains.

Adewole Adamson, MD, MPP: Exploring Key Controversies in Dermatology at the 2025 AAD Annual Meeting

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Michael Gold, MD: Mastering Device Complications and the Importance of Preparedness in Dermatology

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Understanding the Controversies in Lasers and Infantile Hemangiomas

Denise W. Metry, MD, FAAD, explored the controversies in using lasers in infantile hemangiomas at the AAD Annual Meeting.

Day 4

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Peter Lio, MD: Minimizing Discomfort in Dermatologic Procedures

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD

Brian S. Kim, MD, FAAD, shares itch research updates at the AAD Annual Meeting.

Jeff Stark, MD: Discussing Bimzelx’s Efficacy and Future in Treating Inflammatory Skin Diseases

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Michael Gold, MD: Insights on Silicone, Energy-Based Devices, and Radiation Therapy

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

How to Avoid Complications With Radiofrequency and Ultrasound-Based Technologies

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Day 5

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Lebrikizumab Shows 3-Year Sustained Efficacy in AD

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Michael Gold, MD: Advances in Acne Treatment and Energy-Based Devices

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Late-Breaking ESK-001 Data from the OLE STRIDE Trial Presented at AAD 2025

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

Additional Content

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Robert Bissonnette, MD: Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis

Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

Monica K. Li, MD: Global Innovations, Integration with Other Modalities, and Future Trends in Microneedling

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

Mastering Dermoscopy and Dysplastic Nevi

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.

Closing Out AAD With Dermatology Times’ Editor in Chief

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.